Safety and effectiveness of empagliflozin in clinical practice as monotherapy or with other glucose-lowering drugs in Japanese patients with type 2 diabetes: subgroup analysis of a 3-year post-marketing surveillance study
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Safety and effectiveness of empagliflozin in clinical practice as monotherapy or with other glucose-lowering drugs in Japanese patients with type 2 diabetes: subgroup analysis of a 3-year post-marketing surveillance study
Authors
Keywords
-
Journal
Expert Opinion On Drug Safety
Volume -, Issue -, Pages 1-14
Publisher
Informa UK Limited
Online
2023-05-17
DOI
10.1080/14740338.2023.2213477
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Addressing screams for evidence on renoprotection by GLP-1 receptor agonists
- (2022) Takayoshi Sasako et al. KIDNEY INTERNATIONAL
- Safety and effectiveness of empagliflozin in Japanese patients with type 2 diabetes: final results of a 3-year post-marketing surveillance study
- (2022) Kohei Kaku et al. Expert Opinion On Drug Safety
- Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
- (2022) Melanie J. Davies et al. DIABETES CARE
- Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction
- (2022) Scott D. Solomon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effects of tirzepatide versus insulin glargine on kidney outcomes in type 2 diabetes in the SURPASS-4 trial: post-hoc analysis of an open-label, randomised, phase 3 trial
- (2022) Hiddo J L Heerspink et al. Lancet Diabetes & Endocrinology
- Empagliflozin in Patients with Chronic Kidney Disease
- (2022) NEW ENGLAND JOURNAL OF MEDICINE
- A consensus statement from the Japan Diabetes Society: A proposed algorithm for pharmacotherapy in people with type 2 diabetes
- (2022) Ryotaro Bouchi et al. Journal of Diabetes Investigation
- Empagliflozin in Heart Failure with a Preserved Ejection Fraction
- (2021) Stefan D. Anker et al. NEW ENGLAND JOURNAL OF MEDICINE
- Retrospective nationwide study on the trends in first‐line antidiabetic medication for patients with type 2 diabetes in Japan
- (2021) Ryotaro Bouchi et al. Journal of Diabetes Investigation
- Pooled Safety and Tolerability Analysis of Empagliflozin in Patients with Type 2 Diabetes Mellitus
- (2020) Ona Kinduryte Schorling et al. ADVANCES IN THERAPY
- Risk factors for genital infections in people initiating SGLT2 inhibitors and their impact on discontinuation
- (2020) Andrew P McGovern et al. BMJ Open Diabetes Research & Care
- Safety and effectiveness of tofogliflozin in Japanese patients with type 2 diabetes mellitus treated in real‐world clinical practice: Results of J‐STEP/LT, a 36‐month post‐marketing surveillance study
- (2020) Kazunori Utsunomiya et al. Journal of Diabetes Investigation
- GLP-1 Receptor Agonists in Diabetic Kidney Disease: From Clinical Outcomes to Mechanisms
- (2020) Daiji Kawanami et al. Frontiers in Pharmacology
- Real-World Evidence for Long-Term Safety and Effectiveness of Ipragliflozin in Japanese Patients with Type 2 Diabetes Mellitus: final Results of a 3-Year Post-Marketing Surveillance Study (STELLA-LONG TERM)
- (2020) Ichiro Nakamura et al. EXPERT OPINION ON PHARMACOTHERAPY
- Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure
- (2020) Milton Packer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Dapagliflozin in Patients with Chronic Kidney Disease
- (2020) Hiddo J.L. Heerspink et al. NEW ENGLAND JOURNAL OF MEDICINE
- Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
- (2019) Vlado Perkovic et al. NEW ENGLAND JOURNAL OF MEDICINE
- Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
- (2019) John J.V. McMurray et al. NEW ENGLAND JOURNAL OF MEDICINE
- Empagliflozin: A Review in Type 2 Diabetes
- (2018) James E. Frampton DRUGS
- Clinical risk factors predicting genital fungal infections with sodium–glucose cotransporter 2 inhibitor treatment: The ABCD nationwide dapagliflozin audit
- (2018) Ken Yan Thong et al. Primary Care Diabetes
- Empagliflozin Induces Transient Diuresis Without Changing Long-Term Overall Fluid Balance in Japanese Patients With Type 2 Diabetes
- (2018) Atsutaka Yasui et al. Diabetes Therapy
- Empagliflozin Induces Transient Diuresis Without Changing Long-Term Overall Fluid Balance in Japanese Patients With Type 2 Diabetes
- (2018) Atsutaka Yasui et al. Diabetes Therapy
- Baseline Glycated Hemoglobin Values Predict the Magnitude of Glycemic Improvement in Patients with Type 1 and Type 2 Diabetes: Subgroup Analyses from the DIAMOND Study Program
- (2018) Liana K. Billings et al. Diabetes Technology & Therapeutics
- Safety and tolerability of empagliflozin in East Asian patients with type 2 diabetes: Pooled analysis of phase I-III clinical trials
- (2018) Daisuke Yabe et al. Journal of Diabetes Investigation
- Empagliflozin and Kidney Function Decline in Patients with Type 2 Diabetes: A Slope Analysis from the EMPA-REG OUTCOME Trial
- (2018) Christoph Wanner et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
- (2018) Stephen D. Wiviott et al. NEW ENGLAND JOURNAL OF MEDICINE
- Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
- (2017) Bruce Neal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pharmacodynamic Effects of Single and Multiple Doses of Empagliflozin in Patients With Type 2 Diabetes
- (2016) Tim Heise et al. CLINICAL THERAPEUTICS
- Urinary tract and genital infections in patients with type 2 diabetes treated with sodium-glucose co-transporter 2 inhibitors: A meta-analysis of randomized controlled trials
- (2016) Dandan Li et al. DIABETES OBESITY & METABOLISM
- Probing SGLT2 as a therapeutic target for diabetes: Basic physiology and consequences
- (2015) Linda A Gallo et al. Diabetes & Vascular Disease Research
- Impact of empagliflozin added on to basal insulin in type 2 diabetes inadequately controlled on basal insulin: a 78-week randomized, double-blind, placebo-controlled trial
- (2015) J. Rosenstock et al. DIABETES OBESITY & METABOLISM
- Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
- (2015) Bernard Zinman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy and safety of luseogliflozin as monotherapy in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled, phase 3 study
- (2014) Yutaka Seino et al. CURRENT MEDICAL RESEARCH AND OPINION
- Empagliflozin as Add-On to Metformin in Patients With Type 2 Diabetes: A 24-Week, Randomized, Double-Blind, Placebo-Controlled Trial
- (2014) Hans-Ulrich Häring et al. DIABETES CARE
- Improved Glucose Control With Weight Loss, Lower Insulin Doses, and No Increased Hypoglycemia With Empagliflozin Added to Titrated Multiple Daily Injections of Insulin in Obese Inadequately Controlled Type 2 Diabetes
- (2014) Julio Rosenstock et al. DIABETES CARE
- Long-term safety and efficacy of tofogliflozin, a selective inhibitor of sodium-glucose cotransporter 2, as monotherapy or in combination with other oral antidiabetic agents in Japanese patients with type 2 diabetes mellitus: multicenter, open-label, randomized controlled trials
- (2014) Yukio Tanizawa et al. EXPERT OPINION ON PHARMACOTHERAPY
- Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trial
- (2014) Martin Ridderstråle et al. Lancet Diabetes & Endocrinology
- Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial
- (2014) Anthony H Barnett et al. Lancet Diabetes & Endocrinology
- Empagliflozin as Add-on to Metformin Plus Sulfonylurea in Patients With Type 2 Diabetes: A 24-week, randomized, double-blind, placebo-controlled trial
- (2013) H.-U. Haring et al. DIABETES CARE
- Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24-week, randomized, placebo-controlled trial
- (2013) C. S. Kovacs et al. DIABETES OBESITY & METABOLISM
- Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial
- (2013) Michael Roden et al. Lancet Diabetes & Endocrinology
- Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise
- (2012) K. Stenlöf et al. DIABETES OBESITY & METABOLISM
- Low transition rate from normo- and low microalbuminuria to proteinuria in Japanese type 2 diabetic individuals: the Japan Diabetes Complications Study (JDCS)
- (2011) S. Katayama et al. DIABETOLOGIA
- Incidence and progression of diabetic retinopathy in Japanese adults with type 2 diabetes: 8 year follow-up study of the Japan Diabetes Complications Study (JDCS)
- (2011) R Kawasaki et al. DIABETOLOGIA
- Dapagliflozin Monotherapy in Type 2 Diabetic Patients With Inadequate Glycemic Control by Diet and Exercise: A randomized, double-blind, placebo-controlled, phase 3 trial
- (2010) E. Ferrannini et al. DIABETES CARE
- Relationship of baseline HbA1cand efficacy of current glucose-lowering therapies: a meta-analysis of randomized clinical trials
- (2010) R. A. DeFronzo et al. DIABETIC MEDICINE
- Revised Equations for Estimated GFR From Serum Creatinine in Japan
- (2009) Seiichi Matsuo et al. AMERICAN JOURNAL OF KIDNEY DISEASES
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now